Targeting of pre-mRNA by short splice-switching oligonucleotides (SSOs) is increasingly being used as a therapeutic modality, one rationale being to disrupt splicing so as to remove exons containing premature termination codons, or to restore the translation reading frame around out-of-frame deletion mutations. The aim of this study was to investigate the effect of chemically linking individual SSOs so as to ascertain equimolar cellular uptake that would provide for more defined drug formulations. In contrast to conventional bispecific SSOs generated by conjugation in solution, here we describe a protocol for synthesis of bispecific SSOs on solid phase. These SSOs comprised of either a non-cleavable hydrocarbon linker or disulfide-based cleavable linkers. To assess the efficacy of these SSOs we have utilized splice switching to bypass a disease-causing mutation in the DMD gene concurrent with disruption of the reading frame of the myostatin gene (Mstn). The premise of this approach is that disruption of myostatin expression is known to induce muscle hypertrophy and so for Duchenne muscular dystrophy (DMD) could be expected to have a better outcome than dystrophin restoration alone. All tested SSOs mediated simultaneous robust exon removal from mature Dmd and Mstn transcripts in myotubes. Our results also demonstrate that using cleavable SSOs is preferred over the non-cleavable counterparts and that these are equally efficient at inducing exon skipping as cocktails of monospecific versions. In conclusion, we have developed a protocol for solid-phase synthesis of single molecule cleavable bispecific SSOs that can be efficiently exploited for targeting of multiple RNA transcripts.
AARTSMA-RUSA., JANSONA.A., KAMANW.E., BREMMER-BOUTM., DEN DUNNENJ.T., BAASF., VAN OMMENG.J., and VAN DEUTEKOMJ.C. (2003). Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum. Mol. Genet., 12, 907–914.
3.
AARTSMA-RUSA., JANSONA.A., KAMANW.E., BREMMER-BOUTM., VAN OMMENG.J., DEN DUNNENJ.T., and VAN DEUTEKOMJ.C. (2004). Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am. J. Hum. Genet., 74, 83–92.
4.
AARTSMA-RUSA., KAMANW.E., WEIJR., DEN DUNNENJ.T., VAN OMMENG.J., and VAN DEUTEKOMJ.C. (2006). Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol. Ther., 14, 401–407.
5.
ADAMSA.M., HARDINGP.L., IVERSENP.L., COLEMANC., FLETCHERS., and WILTONS.D. (2007). Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Mol. Biol., 8, 57.
6.
ALTERJ., LOUF., RABINOWITZA., YINH., ROSENFELDJ., WILTONS.D., PARTRIDGET.A., and LUQ.L. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nature Med., 12, 175–177.
7.
AOKIY., YOKOTAT., NAGATAT., NAKAMURAA., TANIHATAJ., SAITOT., DUGUEZS.M., NAGARAJUK., HOFFMANE.P., PARTRIDGET., and TAKEDAS. (2012). Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery. Proc. Natl. Acad. Sci. U. S. A., 109, 13763–13768.
8.
BAUMANJ., JEARAWIRIYAPAISARNN., and KOLER. (2009). Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides, 19, 1–13.
9.
BOGDANOVICHS., PERKINSK.J., KRAGT.O., WHITTEMOREL.A., and KHURANAT.S. (2005). Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J., 19, 543–549.
10.
BOGDANOVICHS., and POPOVICD. (2002). Onset of glassy dynamics in a two-dimensional electron system in silicon. Phys. Rev. Lett., 88, 236401.
11.
CACCHIARELLID., INCITTIT., MARTONEJ., CESANAM., CAZZELLAV., SANTINIT., STHANDIERO., and BOZZONII. (2011). miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy. EMBO Rep., 12, 136–141.
12.
CHUNGH.J., HONGC.A., LEES.H., JOS.D., and PARKT.G. (2011). Reducible siRNA dimeric conjugates for efficient cellular uptake and gene silencing. Bioconjug. Chem., 22, 299–306.
13.
CIRAKS., ARECHAVALA-GOMEZAV., GUGLIERIM., FENGL., TORELLIS., ANTHONYK., ABBSS., GARRALDAM.E., BOURKEJ., WELLSD.J., et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet, 378, 595–605.
14.
DUMONCEAUXJ., MARIES., BELEYC., TROLLETC., VIGNAUDA., FERRYA., BUTLER-BROWNEG., and GARCIAL. (2010). Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol. Ther., 18, 881–887.
15.
EL ANDALOUSSIS.A., HAMMONDS.M., MAGERI., and WOODM.J. (2012). Use of cell-penetrating-peptides in oligonucleotide splice switching therapy. Curr. Gene Ther., 12, 161–178.
16.
FAIRBROTHERW.G., YEHR.F., SHARPP.A., and BURGEC.B. (2002). Predictive identification of exonic splicing enhancers in human genes. Science, 297, 1007–1013.
17.
GOEMANSN.M., TULINIUSM., VAN DEN AKKERJ.T., BURMB.E., EKHARTP.F., HEUVELMANSN., HOLLINGT., JANSONA.A., PLATENBURGG.J., SIPKENSJ.A., et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. New Engl. J. Med., 364, 1513–1522.
18.
HEEMSKERKH.A., DE WINTERC.L., DE KIMPES.J., VAN KUIK-ROMEIJNP., HEUVELMANSN., PLATENBURGG.J., VAN OMMENG.J., VAN DEUTEKOMJ.C., and AARTSMA-RUSA. (2009). In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J. Gene Med., 11, 257–266.
19.
HOFFMANE.P., BROWNR.H.JR., and KUNKELL.M. (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell, 51, 919–928.
20.
KANGJ.K., MALERBAA., POPPLEWELLL., FOSTERK., and DICKSONG. (2011a). Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment. Mol. Ther., 19, 159–164.
21.
KANGJ.K., MALERBAA., POPPLEWELLL., FOSTERK., and DICKSONG. (2011b). Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment. Mol. Ther., 19, 159–164.
22.
KEMALADEWID.U., HOOGAARSW.M., VAN HEININGENS.H., TERLOUWS., DE GORTERD.J., DEN DUNNENJ.T., VAN OMMENG.J., AARTSMA-RUSA., TEN DIJKEP., and `T HOENP.A. (2011). Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med. Genomics, 4, 36.
23.
KOLER., KRAINERA.R., and ALTMANS. (2012). RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov., 11, 125–140.
24.
LANGLEYB., THOMASM., BISHOPA., SHARMAM., GILMOURS., and KAMBADURR. (2002). Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J. Biol. Chem., 277, 49831–49840.
25.
LEES.J., and MCPHERRONA.C. (2001). Regulation of myostatin activity and muscle growth. Proc. Natl. Acad. Sci. U. S. A., 98, 9306–9311.
26.
LUQ.L., MANNC.J., LOUF., BOU-GHARIOSG., MORRISG.E., XUES.A., FLETCHERS., PARTRIDGET.A., and WILTONS.D. (2003). Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nature Med., 9, 1009–1014.
27.
LUQ.L., RABINOWITZA., CHENY.C., YOKOTAT., YINH., ALTERJ., JADOONA., BOU-GHARIOSG., and PARTRIDGET. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl. Acad. Sci. U. S. A., 102, 198–203.
28.
MAGEET.R., ARTAZAJ.N., FERRINIM.G., VERNETD., ZUNIGAF.I., CANTINIL., REISZ-PORSZASZS., RAJFERJ., and GONZALEZ-CADAVIDN.F. (2006). Myostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass. J. Gene Med., 8, 1171–1181.
29.
MALERBAA., KANGJ.K., MCCLOREYG., SALEHA.F., POPPLEWELLL., GAITM.J., WOODM.J., and DICKSONG. (2012). Dual Myostatin and dystrophin exon skipping by morpholino nucleic acid oligomers conjugated to a cell-penetrating peptide is a promising therapeutic strategy for the treatment of duchenne muscular dystrophy. Mol. Ther. Nucleic Acids, 1, e62.
30.
MANNC.J., HONEYMANK., MCCLOREYG., FLETCHERS., and WILTONS.D. (2002). Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J. Gene Med., 4, 644–654.
31.
MCCLOREYG., MOULTONH.M., IVERSENP.L., FLETCHERS., and WILTONS.D. (2006). Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther., 13, 1373–1381.
32.
MCCROSKERYS., THOMASM., MAXWELLL., SHARMAM., and KAMBADURR. (2003). Myostatin negatively regulates satellite cell activation and self-renewal. J. Cell Biol., 162, 1135–1147.
33.
MCPHERRONA.C., LAWLERA.M., and LEES.J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 387, 83–90.
34.
MOKH., LEES.H., PARKJ.W., and PARKT.G. (2010). Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat. Mater., 9, 272–278.
35.
MORGANJ.E., BEAUCHAMPJ.R., PAGELC.N., PECKHAMM., ATALIOTISP., JATP.S., NOBLEM.D., FARMERK., and PARTRIDGET.A. (1994). Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev. Biol., 162, 486–498.
36.
MUNTONIF., and WOODM.J. (2011). Targeting RNA to treat neuromuscular disease. Nat. Rev. Drug Discov., 10, 621–637. `1
37.
NAKATANIM., TAKEHARAY., SUGINOH., MATSUMOTOM., HASHIMOTOO., HASEGAWAY., MURAKAMIT., UEZUMIA., TAKEDAS., NOJIS., et al. (2008). Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J., 22, 477–487.
38.
ROBERTST.C., ANDALOUSSIS.E., MORRISK.V., MCCLOREYG., and WOODM.J. (2012a). Small RNA-Mediated Epigenetic Myostatin Silencing. Molecular therapy. Nucleic acids, 1, e23.
39.
ROBERTST.C., BLOMBERGK.E.M., MCCLOREYG., ANDALOUSSIS.E.L., GODFREYC., BETTSC., COURSINDELT., GAITM.J., SMITHC.I.E, and WOODM.J.A. (2012b). Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy. Mol. Ther. Nucleic Acids, 1, e39.
40.
RUBENSTEINM., HOLLOWELLC.M., and GUINANP. (2012). Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR. Med. Oncol., 29, 835–841.
41.
SMITHP.J., ZHANGC., WANGJ., CHEWS.L., ZHANGM.Q., and KRAINERA.R. (2006). An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum. Mol. Genet., 15, 2490–2508.
42.
THOMASM., LANGLEYB., BERRYC., SHARMAM., KIRKS., BASSJ., and KAMBADURR. (2000). Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J. Biol. Chem., 275, 40235–40243.
43.
VAN VLIETL., DE WINTERC.L., VAN DEUTEKOMJ.C., VAN OMMENG.J., and AARTSMA-RUSA. (2008). Assessment of the feasibility of exon 45–55 multiexon skipping for Duchenne muscular dystrophy. BMC Med. Genet., 9, 105.
44.
WAGNERK.R., FLECKENSTEINJ.L., AMATOA.A., BAROHNR.J., BUSHBYK., ESCOLARD.M., FLANIGANK.M., PESTRONKA., TAWILR., WOLFEG.I., et al. (2008). A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol., 63, 561–571.
45.
WOODM.J. (2010). Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge. Sci. Transl. Med., 2, 25ps15.
46.
WUB., LUP., BENRASHIDE., MALIKS., ASHARJ., DORANT.J., and LUQ.L. (2010). Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther., 17, 132–140.
47.
WUB., LUP., CLOERC., SHABANM., GREWALS., MILAZIS., SHAHS.N., MOULTONH.M., and LUQ.L. (2012). Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. Am. J. Pathol., 181, 392–400.
48.
WUB., MOULTONH.M., IVERSENP.L., JIANGJ., LIJ., LIJ., SPURNEYC.F., SALIA., GUERRONA.D., NAGARAJUK., et al. (2008). Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc. Natl. Acad. Sci. U. S. A., 105, 14814–14819.
49.
YINH., MOULTONH.M., BETTSC., MERRITTT., SEOWY., ASHRAFS., WANGQ., BOUTILIERJ., and WOODM.J. (2010). Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol. Ther., 18, 1822–1829.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
